Wondering how best to care for an adult patient with juvenile idiopathic arthritis-associated uveitis or a pediatric patient with early-onset osteoarthritis? Unsure how to manage a 23-year-old with chronic nonbacterial osteomyelitis or an 8-year-old with tophaceous gout due to Lesch-Nyhan syndrome? Ask a Med-Peds rheumatologist. What Is a Med-Peds Rheumatologist? Med-Peds rheumatologists in the U.S….
An ACR-led resolution that calls for Medicaid payment parity for pediatric specialists will become AMA policy.
Experts addressed how changes in research & clinical care can improve outcomes for children experiencing healthcare disparities during a session at the 2023 Pediatric Rheumatology Symposium.
How do inflammatory pathways strain the cardiovascular system? Dr. Mark Gorelik provided insights into the inflammatory processes that influence heart recovery after myocardial infarction, Kawasaki disease, multi-system inflammatory syndrome in children and more.
How do healthcare providers enable positive outcomes for their pediatric patients while also addressing the disparities in care between patients of different ethnicities, gender and socioeconomic backgrounds? Experts addressed how changes in research and clinical care can improve outcomes for children experiencing healthcare disparities during a session at the 2023 Pediatric Rheumatology Symposium.
This program offers loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a three-year, full-time service commitment at an approved facility in an underserved area. Pediatric rheumatologists are encouraged to apply.
“Fifty percent of kids with rheumatic disease are taken care of by adult providers,” says Jay J. Mehta, MD, MS, attending physician and fellowship program director, Department of Rheumatology, Children’s Hospital of Philadelphia, and a co-author of the ACR’s recent pediatric workforce shortage study.1,2 “But adult rheumatologists may not have specific training in the rheumatic…
In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.